Our pipeline includes cabozantinib, our lead compound, and cobimetinib, another Exelixis-discovered compound. In addition, we have other programs that are the subject of partnerships and collaborations.
Exelixis’ internal development efforts are primarily focused on cabozantinib, a targeted agent that inhibits the activity of multiple receptor tyrosine kinases including MET, RET, and VEGFRs, which are implicated in pathological processes such as oncogenesis, metastasis, tumor angiogenesis, and maintenance of the tumor microenvironment. Exelixis has worldwide rights to cabozantinib, which we believe could have the potential to treat a wide variety of cancers.
Cabozantinib is the subject of a broad, global clinical development program that includes approximately 45 ongoing or planned clinical trials. Exelixis is sponsoring multiple randomized phase 3 trials, including METEOR in metastatic renal cell cancer and CELESTIAL in advanced hepatocellular cancer.
For more information on cabozantinib clinical trials, including additional trials conducted as part of our Investigator-Sponsored Trial program and collaboration with the National Cancer Institute’s Cancer Therapy Evaluation Program, please visit the Clinical Trials section of our site.
Cabozantinib is commercially available in the U.S. and EU for a single indication, and it is marketed as COMETRIQ® for that use. For more information, including important safety information and boxed warnings, please visit www.cometriq.com.
Cobimetinib (formerly GDC-0973/XL518)
An Exelixis-discovered compound, cobimetinib is a potent, highly selective inhibitor of MEK, part of the RAS/RAF/MEK/ERK pathway that is frequently dysregulated in human tumors. Cobimetinib is being developed by Roche and Genentech (a member of the Roche Group) under a collaboration agreement with Exelixis. For more information on cobimetinib, visit the compound’s sub-page.
We have established multiple partnerships and collaborations with other leading pharmaceutical and biopharmaceutical companies. These partnerships are designed to advance the development of a variety of potential therapies for cancer and other serious diseases. For more information on our partnered compounds, you can begin exploring their sub-pages here.